S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Closing prices for crude oil, gold and other commodities
BREAKING: Tiny biotech successfully treats blindness (Ad)
MarketBeat Week in Review – 3/27 - 3/31
UN body mulls deep sea mining amid demand for minerals
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
Intensity and insults rise as lawmakers debate debt ceiling
BREAKING: Tiny biotech successfully treats blindness (Ad)
Canada approves largest telecom deal in country's history
Medicare, Social Security could fall short over next decade
NYSE:ZTS

Zoetis - ZTS Stock Forecast, Price & News

$166.44
+2.29 (+1.40%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$164.03
$166.49
50-Day Range
$158.33
$175.02
52-Week Range
$124.15
$201.32
Volume
1.71 million shs
Average Volume
2.02 million shs
Market Capitalization
$77.13 billion
P/E Ratio
36.99
Dividend Yield
0.90%
Price Target
$223.83

Zoetis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
34.5% Upside
$223.83 Price Target
Short Interest
Healthy
0.95% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
-4.66
Upright™ Environmental Score
News Sentiment
0.63mentions of Zoetis in the last 14 days
Based on 21 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
10.95%
From $5.39 to $5.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.51 out of 5 stars

Medical Sector

145th out of 1,004 stocks

Pharmaceutical Preparations Industry

58th out of 489 stocks


ZTS stock logo

About Zoetis (NYSE:ZTS) Stock

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S. market and regulatory activities. The International segment includes non-U.S. market and regulatory activities. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Zoetis Stock Shows Rising Relative Strength Upgrades
Zoetis Inc. (NYSE:ZTS) Q4 2022 Earnings Call Transcript
Zoetis (ZTS) Matches Q4 Earnings Estimates
Zoetis Stock Rises on Expected Sales Growth in 2023
Zoetis Reports Fourth Quarter and Full Year 2022 Results
Why Zoetis Inc. (NYSE:ZTS) Looks Like A Quality Company
See More Headlines
Receive ZTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zoetis and its competitors with MarketBeat's FREE daily newsletter.

ZTS Company Calendar

Ex-Dividend for 3/1 Dividend
1/19/2023
Last Earnings
2/14/2023
Dividend Payable
3/01/2023
Today
4/01/2023
Next Earnings (Confirmed)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
98978V10
Employees
13,800
Year Founded
2012

Price Target and Rating

Average Stock Price Forecast
$223.83
High Stock Price Forecast
$260.00
Low Stock Price Forecast
$180.00
Forecasted Upside/Downside
+34.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$2.11 billion
Pretax Margin
32.87%

Debt

Sales & Book Value

Annual Sales
$8.08 billion
Cash Flow
$5.98 per share
Book Value
$9.45 per share

Miscellaneous

Free Float
462,831,000
Market Cap
$77.13 billion
Optionable
Optionable
Beta
0.76

Social Links


Key Executives

  • Kristin C. PeckKristin C. Peck
    Chief Executive Officer & Director
  • Roxanne LaganoRoxanne Lagano
    Chief Human Resources Officer & Executive VP
  • Wetteny Joseph
    CFO, EVP & Head-Business Development
  • Mike McFarland
    Chief Medical Officer & Executive Vice President
  • Robert J. Polzer
    President-Research & Development, Executive VP













ZTS Stock - Frequently Asked Questions

Should I buy or sell Zoetis stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ZTS shares.
View ZTS analyst ratings
or view top-rated stocks.

What is Zoetis' stock price forecast for 2023?

7 analysts have issued 1-year target prices for Zoetis' shares. Their ZTS share price forecasts range from $180.00 to $260.00. On average, they expect the company's share price to reach $223.83 in the next twelve months. This suggests a possible upside of 34.5% from the stock's current price.
View analysts price targets for ZTS
or view top-rated stocks among Wall Street analysts.

How have ZTS shares performed in 2023?

Zoetis' stock was trading at $146.55 on January 1st, 2023. Since then, ZTS shares have increased by 13.6% and is now trading at $166.44.
View the best growth stocks for 2023 here
.

When is Zoetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our ZTS earnings forecast
.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, May 4th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its earnings results on Tuesday, February, 14th. The company reported $1.15 earnings per share for the quarter, hitting analysts' consensus estimates of $1.15. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Zoetis had a trailing twelve-month return on equity of 50.20% and a net margin of 26.16%. Zoetis's revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter last year, the company posted $1.00 EPS.
Read the conference call transcript
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Wednesday, February 8th. Stockholders of record on Friday, April 21st will be paid a dividend of $0.375 per share on Thursday, June 1st. This represents a $1.50 dividend on an annualized basis and a yield of 0.90%. The ex-dividend date of this dividend is Thursday, April 20th.
Read our dividend analysis for ZTS
.

Is Zoetis a good dividend stock?

Zoetis (NYSE:ZTS) pays an annual dividend of $1.50 per share and currently has a dividend yield of 0.91%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 33.33%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ZTS will have a dividend payout ratio of 25.08% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ZTS.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY 2023 earnings guidance on Tuesday, February, 14th. The company provided earnings per share (EPS) guidance of $5.34-$5.44 for the period, compared to the consensus estimate of $5.33. The company issued revenue guidance of $8.57 billion-$8.72 billion, compared to the consensus revenue estimate of $8.57 billion.

What is Kristin Peck's approval rating as Zoetis' CEO?

50 employees have rated Zoetis Chief Executive Officer Kristin Peck on Glassdoor.com. Kristin Peck has an approval rating of 82% among the company's employees. 70.0% of employees surveyed would recommend working at Zoetis to a friend.

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How do I buy shares of Zoetis?

Shares of ZTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $166.44.

How much money does Zoetis make?

Zoetis (NYSE:ZTS) has a market capitalization of $77.13 billion and generates $8.08 billion in revenue each year. The company earns $2.11 billion in net income (profit) each year or $4.50 on an earnings per share basis.

How many employees does Zoetis have?

The company employs 13,800 workers across the globe.

Does Zoetis have any subsidiaries?
The following companies are subsidiares of Zoetis: Abaxis, Abaxis Asia Limited, Abaxis Europe GmbH, Abaxis Inc., Abaxis South East Europe d. o.o., Abaxis UK Limited, Alpharma Animal Health Company, Alpharma Animal Health Hong Kong Co. Limited, Alpharma Bermuda LLC, Alpharma Euro Holdings LLC, Alpharma Holdings Barbados SRL, Alpharma LLC, Alpharma Luxembourg S.A.R.L. y Compania Limitada, Alpharma do Brasil Ltda., Bovigen, Catapult Genetics Pty Ltd, Continental Farmaceutica SPRL, Cross Vetpharm Group Limited, Embrex LLC, Ethos Diagnostic Science, Fish Vet Group, Fish Vet Group Limited, Jilin Zoetis Guoyuan Animal Health Co. Ltd., Jorox Pty, King Animal Health, Microtek International Inc, Mikjan Corporation, Nexvet, Nexvet Australia Pty Ltd, PAH 7V6 Holding Limited, PAH CHHK Holding B.V., PAH India Holdco LLC, PAH India Holding 1 B.V., PAH Netherlands 2 B.V., PAH Oceania B.V., PAH Spain S.L., PHARMAQ, PT Zoetis Animalhealth Indonesia, Performance Livestock Analytics, Performance Livestock Analytics Inc., Pharmaq AS Chile Limitada, Pharmaq AS Service SpA, Pharmaq AS., Pharmaq Analytiq AS, Pharmaq Analytiq Limited, Pharmaq Analytiq SpA, Pharmaq Fishteq AS, Pharmaq Fishteq SpA, Pharmaq Ltd, Pharmaq Spain Aqua SL, Pharmaq Veterinar Ecza Deposu ve su Urunleri Ticaret Ltd Ski, Pharmaq Vietnam Company Limited, Phoenix Central Laboratory for Veterinarians Inc., Phoenix Lab, Platinum Performance, Platinum Performance Inc., Pumpkin Holdings Inc., Pumpkin Insurance Services Inc., Scandinavian Micro Biodevices, Smartbow GmbH, Smartbow RUS OOO, Synbiotics Corporation, Synbiotics LLC, Vetnex Animal Health Ltd, Virtual Recall, Virtual Recall Limited, Virtual Recall Pty Ltd, ZNLabs, ZNLabs LLC, ZOETISECUADOR Cia. Ltda., Zoetis Animal Health ApS, Zoetis Argentina S.R.L., Zoetis Australia Pty Ltd, Zoetis Australia Research & Manufacturing Pty Ltd, Zoetis B.V., Zoetis Belgium S.A., Zoetis Biopharmaceutical Co. Ltd, Zoetis Broomhill IP Limited, Zoetis Broomhill Property Limited, Zoetis C.A., Zoetis Canada Inc., Zoetis Colombia S.A.S., Zoetis Costa Rica S.R.L., Zoetis Denmark ApS, Zoetis Deutschland GmbH, Zoetis Egypt LLC, Zoetis Egypt Pharmaceuticals LLC, Zoetis Egypt Trading LLC, Zoetis Enterprise Management Shanghai Co. Ltd., Zoetis Finland Oy, Zoetis France, Zoetis Hayvan Sagligi Ltd. Sti., Zoetis Hellas S.A., Zoetis Holdings LLC, Zoetis Hungary Kft., Zoetis Import Egypt LLC, Zoetis India Limited, Zoetis Indústria de Produtos Veterinários Ltda., Zoetis International Holdings B.V., Zoetis Israël Holding B.V., Zoetis Italia S.r.l., Zoetis Japan K.K., Zoetis Korea Ltd., Zoetis LLC, Zoetis Luxembourg Holding S.à r.l., Zoetis Malaysia Sdn. Bhd., Zoetis Manufacturing & Research Spain S.L., Zoetis Manufacturing Italia S.R.L., Zoetis Medolla Manufacturing S.R.L., Zoetis Mexico S. de R.L. de C.V., Zoetis Netherlands 1 B.V., Zoetis Netherlands 3 B.V., Zoetis Netherlands 4 B.V., Zoetis Netherlands 5 B.V., Zoetis New Zealand Limited, Zoetis OOO, Zoetis Overseas Holding B.V., Zoetis Overseas Services Inc., Zoetis Panama S. de R.L., Zoetis Pharmaceutical Research Private Limited, Zoetis Philippines Inc., Zoetis Polska sp. z o.o, Zoetis Portugal Lda., Zoetis Products Inc., Zoetis Reference Laboratories China Co. Ltd., Zoetis Reference Labs LLC, Zoetis Romania SRL, Zoetis S.R.L., Zoetis Salud Animal de Bolivia S.A., Zoetis Schweiz GmbH, Zoetis Services LLC, Zoetis Singapore Pte. Ltd., Zoetis South Africa Pty Ltd., Zoetis Spain S.L., Zoetis Subsidiary Holdings Inc., Zoetis Suzhou Manufacturing Co. Ltd., Zoetis Sweden AB, Zoetis Taiwan Limited, Zoetis Thailand Limited, Zoetis Treasury Center BV, Zoetis UK Limited, Zoetis US LLC, Zoetis Ukraine LLC, Zoetis Vietnam Limited Liability Company, Zoetis WLC LLC, Zoetis Weesp B.V., Zoetis Yantai Manufacturing Co. Ltd., Zoetis de Chile S.A., Zoetis de Uruguay S.R.L., Zoetis Österreich GmbH, and Zoetis Česká republika s.r.o..
Read More
How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The official website for the company is www.zoetis.com. The company can be reached via phone at (973) 822-7000, via email at steve.frank@zoetis.com, or via fax at 302-655-5049.

This page (NYSE:ZTS) was last updated on 4/1/2023 by MarketBeat.com Staff